Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data

Settino, 2020, MMRF-coMMpass data integration and analysis for identifying prognostic markers, 564 Szalat, 2016, Gene expression profiles in myeloma: ready for the real world?, Clin. Cancer Res., 22, 5434, 10.1158/1078-0432.CCR-16-0867 Gooding, 2019, Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease, Nat. Commun., 10, 4533, 10.1038/s41467-019-12296-1 Kuiper, 2012, A gene expression signature for high-risk multiple myeloma, Leukemia, 26, 2406, 10.1038/leu.2012.127 Chng, 2016, Gene signature combinations improve prognostic stratification of multiple myeloma patients, Leukemia, 30, 1071, 10.1038/leu.2015.341 Arbitrio, 2018, Pharmacogenomic profiling of adme gene variants: current challenges and validation perspectives, High Throughput, 7, 10.3390/ht7040040 Arbitrio, 2016, DMETTM (drug metabolism enzymes and transporters): a pharmacogenomic platform for precision medicine, Oncotarget, 7, 10.18632/oncotarget.9927 Di Martino, 2011, A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling, Br. J. Haematol., 154, 529, 10.1111/j.1365-2141.2011.08622.x Di Martino, 2011, S ingle nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study, Cancer Biol. Ther., 12, 780, 10.4161/cbt.12.9.17781 Arbitrio, 2016, Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis, Cancer Chemother. Pharmacol., 77, 205, 10.1007/s00280-015-2916-3 Di Martino, 2016, Genetic variants associated with gastrointestinal symptoms in Fabry disease, Oncotarget, 7, 85895, 10.18632/oncotarget.13135 Arbitrio, 2019, Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in patients with breast cancer: a case-control study, Clin. Pharmacol. Ther., 106, 422, 10.1002/cpt.1391 Scionti, 2017, Genetic variants associated with Fabry disease progression despite enzyme replacement therapy, Oncotarget, 8, 107558, 10.18632/oncotarget.22505 Agapito, 2020, DMETTM genotyping: tools for biomarkers discovery in the era of precision medicine, High Throughput, 9, 10.3390/ht9020008 Agapito, 2015, DMET-Miner: efficient discovery of association rules from pharmacogenomic data, J. Biomed. Informatics, 56, 273, 10.1016/j.jbi.2015.06.005 Mounir, 2019, New functionalities in the tcgabiolinks package for the study and integration of cancer data from gdc and gtex, PLoS Comput. Biol., 15, 10.1371/journal.pcbi.1006701 Silva, 2016, TCGA Workflow: analyze cancer genomics and epigenomics data using Bioconductor packages, F1000Res, 5, 1542, 10.12688/f1000research.8923.1 Colaprico, 2016, Tcgabiolinks: an r/bioconductor package for integrative analysis of tcga data, Nucleic Acids Res., 44, 10.1093/nar/gkv1507 Jensen, 2017, The nci genomic data commons as an engine for precision medicine, Blood, 130, 453, 10.1182/blood-2017-03-735654 Lee, 2018, Data harmonization for a molecularly driven health system, Cell, 174, 1045, 10.1016/j.cell.2018.08.012 Weinstein, 2013, The Cancer Genome Atlas pan-cancer analysis project, Nat. Genet., 45, 1113, 10.1038/ng.2764 Sun, 2019, Prognostic model for multiple myeloma progression integrating gene expression and clinical features, Gigascience, 8, 10.1093/gigascience/giz153 Rupji, 2019, NOJAH: NOt Just Another Heatmap for genome-wide cluster analysis, PLoS ONE, 14, e0204542, 10.1371/journal.pone.0204542 Ubels, 2018, Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects, Nat. Commun., 9, 2943, 10.1038/s41467-018-05348-5 Liu, 2019, A network analysis of multiple myeloma related gene signatures, Cancers (Basel), 11, 10.3390/cancers11101452 Liu, 2019, A network analysis of multiple myeloma related gene signatures, Cancers (Basel), 11, 10.3390/cancers11101452 Clough, 2016, The gene expression omnibus database, Methods Mol. Biol., 1418, 93, 10.1007/978-1-4939-3578-9_5 Barrett, 2013, NCBI GEO: archive for functional genomics data sets-update, Nucleic Acids Res., 41, D991 Huber, 2015, Orchestrating high-throughput genomic analysis with Bioconductor, Nat. Methods, 12, 115, 10.1038/nmeth.3252 Huber, 2015, Orchestrating high-throughput genomic analysis with bioconductor, Nat. Methods, 12, 115, 10.1038/nmeth.3252 Mounir, 2019, New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx, PLOS Comput. Biol., 15, e1006701, 10.1371/journal.pcbi.1006701 Finotello, 2014, Measuring differential gene expression with RNA-seq: challenges and strategies for data analysis, Brief. Funct. Genomics, 14, 130, 10.1093/bfgp/elu035 McDermaid, 2019, Interpretation of differential gene expression results of RNA-seq data: review and integration, Brief Bioinform., 20, 2044, 10.1093/bib/bby067 Clark, 2003, Survival analysis Part I: basic concepts and first analyses, Br. J. Cancer, 89, 232, 10.1038/sj.bjc.6601118 Kaplan, 1958, Nonparametric estimation from incomplete observations, J. Am. Stat. Assoc., 53, 457, 10.1080/01621459.1958.10501452 A. Fritz, C. Percy, A. Jack, K. Shanmugaratnam, L.H. Sobin, D.M. Parkin, S.L. Whelan, World Health Organization, “international classification of diseases for oncology”. English edition reprinted in 2001, 2005, 2007, 2009, 2012, 2000. O’Connell, 2004, Cd138 (syndecan-1), a plasma cell marker: immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms, Am. J. Clin. Pathol., 121, 254, 10.1309/617DWB5GNFWXHW4L Risso, 2011, GC-content normalization for RNA-Seq data, BMC Bioinformatics, 12, 480, 10.1186/1471-2105-12-480 Bullard, 2010, Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments, BMC Bioinformatics, 11, 94, 10.1186/1471-2105-11-94 Kumar, 2016, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol., 17, e328, 10.1016/S1470-2045(16)30206-6 Durie, 2006, International uniform response criteria for multiple myeloma, Leukemia, 20, 1467, 10.1038/sj.leu.2404284 Zach, 2006, Tumor cell detection in peripheral blood and bone marrow, Curr. Opin. Oncol., 18, 48, 10.1097/01.cco.0000198973.51615.fa Asuero, 2006, The correlation coefficient: an overview, Crit. Rev. Anal. Chem., 36, 41, 10.1080/10408340500526766 Huang, 2009, Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists, Nucleic Acids Res., 37, 1, 10.1093/nar/gkn923 Li, 2020, Expression profile of ACTL8, CTCFL, OIP5 and XAGE3 in glioma and their prognostic significance: a retrospective clinical study, Am. J. Transl. Res., 12, 7782 Kumar, 2016, Cancer/testis antigens as molecular drug targets using network pharmacology, Tumour Biol., 10.1007/s13277-016-5333-2 Martelange, 2000, Identification on a human sarcoma of two new genes with tumor-specific expression, Cancer Res., 60, 3848 Li, 2019, KCNK levels are prognostic and diagnostic markers for hepatocellular carcinoma, Aging (Albany NY), 11, 8169, 10.18632/aging.102311 Voloshyna, 2008, TREK-1 is a novel molecular target in prostate cancer, Cancer Res., 68, 1197, 10.1158/0008-5472.CAN-07-5163 Chen, 2019, The expanded role of fatty acid metabolism in cancer: new aspects and targets, Precis. Clin. Med., 2, 183, 10.1093/pcmedi/pbz017 Nguyen, 2017, EphA5 and EphA7 forward signaling enhances human hematopoietic stem and progenitor cell maintenance, migration, and adhesion via Rac1 activation, Exp. Hematol., 48, 72, 10.1016/j.exphem.2016.12.001 Zhang, 2020, EphA5 knockdown enhances the invasion and migration ability of esophageal squamous cell carcinoma via epithelial-mesenchymal transition through activating Wnt/β-catenin pathway, Cancer Cell Int., 20, 20, 10.1186/s12935-020-1101-x Chen, 2016, EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma, J. Ovarian Res., 9, 83, 10.1186/s13048-016-0292-1